II - OTHER INFORMATION
1. Legal Proceedings.
time to time, we and our subsidiaries may be involved in routine litigation incidental to the conduct of our business. We are
not presently a party to any pending litigation.
1A. Risk Factors
Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results
may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important
factors that could affect our actual future results, including our proposed operations, business prospects and financial condition.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business
operations. In addition to the risks described below and the risk factors found in our Annual Report on Form 10-K, as amended,
for the year ended December 31, 2017, you should carefully consider all of the other information included in this Report and in
that Annual Report on Form 10-K, as well as our other publicly available filings with the U.S. Securities and Exchange Commission
have incurred operating losses since inception and we do not know if we will attain profitability.
operating losses for the three months ended March 31, 2018 and for the fiscal years ended December 31, 2017 and 2016, were $12.2
million, $38.9 million and $59.0 million, respectively, and we had an accumulated deficit of $279.4 million as of March 31, 2018.
We primarily finance our operations through the sale of equity securities, licensing fees, royalties on product sales by our licensees,
research grants, and subscription fees and advertising revenue from database products. Ultimately, our ability to generate sufficient
operating revenue to earn a profit depends upon our and our subsidiaries’ success in developing and marketing or licensing
products and technology.
will spend a substantial amount of our capital on research and development but we might not succeed in developing products and
technologies that are useful in medicine.
are attempting to develop new medical products and technology. None of our experimental products and technologies has received
regulatory approval for commercialization. These new products and technologies might not prove to be safe and efficacious in the
human medical applications for which they are being developed. The experimentation we are doing is costly, time consuming, and
uncertain as to its results. We incurred research and development expenses amounting to $6.7 million during the three months ended
March 31, 2018, and $24.0 million and $36.1 million during the fiscal years ended December 31, 2017 and 2016, respectively. If
we are successful in developing a new technology or products, refinement of the new technology or product and definition of the
practical applications and limitations of the technology or product may take years and require the expenditure of large sums of
money. Clinical trials of new therapeutic products, particularly those products that are regulated as biologics, drugs, or devices,
will be very expensive and will take years to complete. We may not have the financial resources to fund clinical trials on our
own and we may have to enter into licensing or collaborative arrangements with other companies. Any such arrangements may be dilutive
to our ownership or economic interest in the products we develop, and we might have to accept royalty payments on the sale of
products rather than receiving the gross revenues from product sales. In addition, we may discontinue one or more of the research
or product development programs. Other programs slated for development including those we consolidate in a new subsidiary, AgeX,
may be delayed or discontinued should adequate funding on acceptable terms not be available.
amount and pace of research and development work that we and our subsidiaries can do or sponsor, and our ability to commence and
complete clinical trials required to obtain regulatory approval to market our therapeutic and medical device products, depends
upon the amount of money we have.
March 31, 2018, we had $31.4 million of cash, cash equivalents and marketable equity securities on hand, which includes $8.5 million
of cash held by AgeX and its subsidiaries. Although BioTime and subsidiaries combined have raised a total of approximately $0.7
million of net proceeds through the sale of equity securities and $3.2 million in cash from sale AgeX shares of Ascendance common
stock, there can be no assurance that we or our subsidiaries will be able to raise additional funds on favorable terms or at all,
or that any funds raised will be sufficient to permit us or our subsidiaries to develop and market our products and technology.
Unless we and our subsidiaries are able to generate sufficient revenue or raise additional funds when needed, it is likely that
we will be unable to continue our planned activities, even if we make progress in our research and development projects. We may
have to postpone or limit the pace of our research and development work and planned clinical trials of our product candidates
unless our cash resources increase through a growth in revenues or additional equity investment or borrowing.